Ovarian Cancer Trial Results
Expanding the Playing Field: Immune-Based Therapy Shows Potential for Lung, Other Cancers
(Posted: 06/15/2012) - Results from two early-phase clinical trials presented at the 2012 American Society of Clinical Oncology annual meeting provide further evidence that priming the immune system to attack tumors has potential as a treatment for certain cancers.
Combining Chemotherapy with Bevacizumab Improves Outcomes for Ovarian Cancer Patients
(Posted: 06/29/2011, Updated: 04/25/2012) - Results from two phase III randomized clinical trials suggest that, at least for some patients with ovarian cancer, adding the antiangiogenesis agent bevacizumab to chemotherapy increases the time to disease progression and may improve survival.
Ovarian Cancer Screening Method Fails to Reduce Deaths from the Disease
(Posted: 07/27/2011) - New results from the NCI-sponsored Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial show that screening for ovarian cancer with transvaginal ultrasound (TVU) and the CA-125 blood test did not result in fewer deaths from the disease compared with usual care.
When Combined with Chemotherapy, Bevacizumab Is Associated with Increased Risk of Death
(Posted: 03/30/2011) - Cancer patients who receive the targeted therapy bevacizumab (Avastin) in combination with chemotherapy are at increased risk of serious side effects that may lead to death, according to a meta-analysis of 16 clinical trials that was published February 2, 2011, in JAMA.
Early Chemotherapy to Prevent Ovarian Cancer Recurrence Fails to Increase Survival
(Posted: 06/19/2009, Updated: 11/05/2010) - Women in remission for ovarian cancer who started chemotherapy to prevent a recurrence based on blood levels of the protein CA125 did not live longer than women who started chemotherapy only after symptoms of the disease arose, according to findings presented at the 2009 ASCO meeting in Orlando.
(Posted: 06/15/2012) - Results from two early-phase clinical trials presented at the 2012 American Society of Clinical Oncology annual meeting provide further evidence that priming the immune system to attack tumors has potential as a treatment for certain cancers.
Combining Chemotherapy with Bevacizumab Improves Outcomes for Ovarian Cancer Patients
(Posted: 06/29/2011, Updated: 04/25/2012) - Results from two phase III randomized clinical trials suggest that, at least for some patients with ovarian cancer, adding the antiangiogenesis agent bevacizumab to chemotherapy increases the time to disease progression and may improve survival.
Ovarian Cancer Screening Method Fails to Reduce Deaths from the Disease
(Posted: 07/27/2011) - New results from the NCI-sponsored Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial show that screening for ovarian cancer with transvaginal ultrasound (TVU) and the CA-125 blood test did not result in fewer deaths from the disease compared with usual care.
When Combined with Chemotherapy, Bevacizumab Is Associated with Increased Risk of Death
(Posted: 03/30/2011) - Cancer patients who receive the targeted therapy bevacizumab (Avastin) in combination with chemotherapy are at increased risk of serious side effects that may lead to death, according to a meta-analysis of 16 clinical trials that was published February 2, 2011, in JAMA.
Early Chemotherapy to Prevent Ovarian Cancer Recurrence Fails to Increase Survival
(Posted: 06/19/2009, Updated: 11/05/2010) - Women in remission for ovarian cancer who started chemotherapy to prevent a recurrence based on blood levels of the protein CA125 did not live longer than women who started chemotherapy only after symptoms of the disease arose, according to findings presented at the 2009 ASCO meeting in Orlando.
